Service Line:+86-022-82164980
Address:FL-4, Building A5, International Enterprise Community, Tianjin, China
Email:[email protected]
Catalog Number | YR1487 |
---|---|
Product Name | Anti-Human CD223 Recombinant Antibody(Relatlimab) |
Molecular Name | Relatlimab |
Alias | Anti-CD223 Recombinant Antibody, Research Grade Relatlimab |
CAS Number | 1673516-98-7 |
Target | CD223[Homo sapiens] |
Isotype | IgG4 Kappa |
Clonity | Monoclonal |
Source | CHO Cells |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Purity | >95% as determined by SDS-PAGE |
Buffer | PBS, pH7.5 |
Background | Relatlimab (INN, development code BMS-986016) is a monoclonal antibody designed for the treatment of melanoma. This drug is being developed by Bristol-Myers Squibb. As of 2018, relatlimab is undergoing Phase II/III trials. |
Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Note | This product is for research use only. |